enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Abituzumab - Wikipedia

   en.wikipedia.org/wiki/Abituzumab

   Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer. [1] [2]

3. Indium (111In) capromab pendetide - Wikipedia

   en.wikipedia.org/wiki/Indium_(111In)_capromab...

   Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide , a derivative of DTPA . [ 2 ] Pendetide acts as a chelating agent for the radionuclide indium-111 .

4. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.

5. Tocilizumab - Wikipedia

   en.wikipedia.org/wiki/Tocilizumab

   It is a recombinant humanized monoclonal antibody of the immunoglobulin IgG1 subclass against the interleukin-6 receptor (IL-6R). [18] Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.

6. Ipilimumab - Wikipedia

   en.wikipedia.org/wiki/Ipilimumab

   Ipilimumab, in combination with nivolumab, is indicated for the treatment of adults and adolescents twelve years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

7. Leronlimab - Wikipedia

   en.wikipedia.org/wiki/Leronlimab

   Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system.It is being investigated as a potential therapy in the treatment of COVID-19, [1] [2] triple negative breast cancer, [3] and HIV infection. [4]